Brinsulrapi H 40 IU/ml

Diabetes mellitus (type 1) in adults, diabetes mellitus (type 2) (in the case of resistance to oral hypoglycemic agents, including partial during combination therapy, against the background of intercurrent diseases, during pregnancy).

P / c, i / m, I / v 3 times a day (if necessary, 5-6 times a day), the dose and method of administration are determined individually. After 30 minutes after administration, it is necessary to take food. A daily dose exceeding 0.6 U / kg should be administered in the form of two or more injections in different areas of the body. Treatment can be combined with the use of long-acting insulin.

Hypersensitivity, hypoglycemia.

Hypoglycemia, allergic reactions (skin rash), transient refractive errors (usually at the beginning of therapy), with prolonged use — lipodystrophy at the injection site.

Symptoms: a sharp increase in sweating, palpitations, tremors, hunger, agitation, paresthesia in the mouth, pallor of the skin, headache, in severe cases — hypoglycemic coma.

Treatment: ingestion of sugar or foods rich in carbohydrates, in severe cases, when the patient loses consciousness-the introduction of glucose (40% solution in/in) and glucagon (in/m).

• Insulins

MAO inhibitors, non-selective beta-blockers, sulfonamides, anabolic steroids, tetracyclines, clofibrate, cyclophosphamide, fenfluramine and drugs containing ethanol, enhance the hypoglycemic effect, oral contraceptives, glucocorticoids, thyroid hormones, thiazide diuretics, heparin, lithium preparations and tricyclic antidepressants — weaken. Reserpine and salicylates can both weaken and enhance the hypoglycemic effect.

In a place protected from light, at a temperature of 2-8 °C. Do not allow freezing.

Keep out of reach of children.

Do not use after the expiration date indicated on the package.

1 ml of the solution for injection contains 40 units of neutral human insulin, as well as 3 mg of metacresol, glycerin as a preservative, in glass bottles of 10 ml, in a cardboard pack of 1 bottle.

Patients receiving more than 100 units / day of Brinsulrapi H, when changing the drug, it is advisable to be hospitalized.

The transition from one type of insulin to another should be carried out under the control of blood glucose levels.

With the initial appointment, a change in the type of insulin or the occurrence of stressful situations during treatment, it is possible to reduce the ability to drive vehicles and mechanisms, to other potentially dangerous activities that require increased attention and speed of reaction.

With changes in the nature and diet, significant physical exertion, infectious diseases, surgical interventions, pregnancy, thyroid dysfunction, Addison's disease, hypopituitarism, renal failure, and in patients over 65 years of age, it is necessary to adjust the dose.

Insulin lowers the tolerance for alcohol.

A10AB Short-acting insulins and their analogues for injection

• E14 Diabetes mellitus, unspecified